Both European and American trials showed superior effect of ulipristal acetate (UPA) to placebo. However, the latter, which included black patients with known higher vitaminD3 deficiency risk, showed lower rate of amenorrhea responders and insignificant uterine fibroid (UF) size reduction. Our objective is to investigate whether adding vitamin D3 to UPA can enhance UPA potency on UF phenotype in vitro.
Methods:
We screened the antiproliferative effect of different (UPA/vitaminD3) combinations on UF cell proliferation using dimethylthiazolyl diphenyltetrazolium bromide assay. Cells then were treated with UPA 100 nM in the presence or absence of vitamin D3 100 nM, and expression level of several markers related to proliferation, apoptosis, fibrosis, inflammation, and angiogenesis was measured on RNA or at protein level using quantitative real-time polymerase chain reaction, Western blot, immunofluorescence, or multiplex enzyme-linked immunosorbent assay techniques.
Results:
Significant dose- and time-dependent growth inhibitory effects of UPA/vitamin D3 combinations were observed compared to untreated cells at 2 and 4 days (P < .05). Importantly, vitamin D3/UPA combination significantly reduced cell proliferation as compared to UPA at 2, 4, 6, and 8 days (P < .05). Combination treatment significantly decreased protein expression of proliferation markers Ki-67, PCNA, and CyclinD1 by more than 50% compared to UPA (P < .05) along with a significant increase in apoptosis induction. Combination treatment resulted in a 2-fold decrease in protein levels of extracellular matrix markers collagen-1 and fibronectin besides pro-fibrogenic cytokine transforming growth factor β3 (P < .05). Moreover, it significantly decreased the production of pro-inflammatory cytokines interleukins 6, 8, 1α, and 1β compared to UPA (P < .05).
Conclusion:
Combination of vitamin D3 with UPA exhibits additional and orchestrated anti-UF effects, therefore might offer a more favorable clinical option.
AliMAl-HendyA. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod. 2017;97(3):337–352.
3.
CardozoERClarkADBanksNKHenneMBStegmannBJSegarsJH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211 e211–e219.
4.
AliMChaudhryZTAl-HendyA. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018;13(2):169–177.
5.
Al-HendyAMyersERStewartE. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35(6):473–480.
DonnezJDonnezOMatuleD. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–173 e164.
8.
SimonJACatherinoWSegarsJH. Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;131(3):431–439.
9.
DonnezJTatarchukTFBouchardP. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–420.
10.
StewartEACooksonCLGandolfoRASchulze-RathR. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–1512.
11.
Oskovi KaplanZATasciYTopcuHOErkayaS. 25-hydroxy vitamin D levels in premenopausal Turkish women with uterine leiomyoma. Gynecol Endocrinol. 2018;34(3):261–264.
12.
PaffoniASomiglianaEViganoP. Vitamin D status in women with uterine leiomyomas. J Clin Endocrinol Metab. 2013;98(8):E1374–E378.
13.
CiavattiniADelli CarpiniGSerriM. Hypovitaminosis D and “small burden” uterine fibroids: opportunity for a vitamin D supplementation. Medicine (Baltimore). 2016;95(52):e5698.
14.
BraktaSDiamondJSAl-HendyADiamondMPHalderSK. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015;104(3):698–706.
15.
IslamMSCiavattiniAPetragliaFCastellucciMCiarmelaP. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018;24(1):59–85.
16.
YoshidaSOharaNXuQ. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010;28(3):260–273.
17.
BairdDDHillMCSchectmanJMHollisBW. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013;24(3):447–453.
18.
RoshdyERajaratnamVMaitraSSabryMAllahASAl-HendyA. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health. 2013;5:477–486.
19.
XuQTakekidaSOharaN. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5’-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005;90(2):953–961.
20.
CheginiN. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28(3):180–203.
21.
WalkerCLStewartEA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589–1592.
22.
DixonDFlakeGPMooreAB. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002;441(1):53–62.
23.
SharanCHalderSKThotaCJaleelTNairSAl-HendyA. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95(1):247–253.
24.
HalderSKSharanCAl-HendyA. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86(4):116.
25.
CsatlosEMateSLakyMRigoJJrJooJG. Role of apoptosis in the development of uterine leiomyoma: analysis of expression patterns of bcl-2 and bax in human leiomyoma tissue with clinical correlations. Int J Gynecol Pathol. 2015;34(4):334–339.
26.
HuangSCTangMJHsuKFChengYMChouCY. Fas and its ligand, caspases, and bcl-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma. J Clin Endocrinol Metab. 2002;87(10):4580–4586.
27.
IwahashiMMuragakiY. Increased type I and V collagen expression in uterine leiomyomas during the menstrual cycle. Fertil Steril. 2011;95(6):2137–2139.
28.
StewartEAFriedmanAJPeckKNowakRA. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab. 1994;79(3):900–906.
29.
MalikMNorianJMcCarthy-KeithDBrittenJCatherinoWH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med. 2010;28(3):169–179.
30.
AriciASozenI. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73(5):1006–1011.
31.
XuQOharaNLiuJ. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14(3):181–191.
32.
LewisTDMalikMBrittenJLCatherinoWH. Ulipristal acetate decreases leiomyoma extracellular matrix through upregulation of nuclear receptor subfamily 4 members. Fertil Steril. 2017;108(3):e204.
33.
CoxJMalikMBrittenJLewisTCatherinoWH. Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial. Reprod Sci. 2018;25(2):198–206.
34.
CourtoyGEDonnezJMarbaixEDolmansMM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104(2):426–434 e421.
35.
HalderSKOsteenKGAl-HendyA. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013;89(6):150.
36.
HalderSKGoodwinJSAl-HendyA. 1,25-dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96(4):E754–E762.
37.
NorianJMMalikMParkerCY. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16(12):1153–1164.
38.
JosephDSMalikMNurudeenSCatherinoWH. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril. 2010;93(5):1500–1508.
39.
WolanskaMSobolewskiKBankowskiEJaworskiS. Matrix metalloproteinases of human leiomyoma in various stages of tumor growth. Gynecol Obstet Invest. 2004;58(1):14–18.
40.
TsigkouAReisFMCiarmelaP. Expression levels of myostatin and matrix metalloproteinase 14 mRNAs in uterine leiomyoma are correlated with dysmenorrhea. Reprod Sci. 2015;22(12):1597–1602.
41.
RodriguezDMorrisonCJOverallCM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 2010;1803(1):39–54.
42.
HalderSKOsteenKGAl-HendyA. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28(9):2407–2416.
43.
DayerCStamenkovicI. Recruitment of matrix metalloproteinase-9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase 3 (LH3) triggers transforming growth factor-beta (TGF-beta) activation and fibroblast differentiation. J Biol Chem. 2015;290(22):13763–13778.
44.
IkenakaYYoshijiHKuriyamaS. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer. 2003;105(3):340–346.
45.
PlewkaAMadejPPlewkaD. Immunohistochemical localization of selected pro-inflammatory factors in uterine myomas and myometrium in women of various ages. Folia Histochem Cytobiol. 2013;51(1):73–83.
46.
ProticOTotiPIslamMS. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res. 2016;364(2):415–427.
47.
WynnTA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.
48.
WangYFengGWangJ. Differential effects of tumor necrosis factor-alpha on matrix metalloproteinase-2 expression in human myometrial and uterine leiomyoma smooth muscle cells. Hum Reprod. 2015;30(1):61–70.
49.
IslamMSCatherinoWHProticO. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J Clin Endocrinol Metab. 2014;99(5):E775–E785.
50.
NairSAl-HendyA. Adipocytes enhance the proliferation of human leiomyoma cells via TNF-alpha proinflammatory cytokine. Reprod Sci. 2011;18(12):1186–1192.
51.
ThotaCFarmerTGarfieldREMenonRAl-HendyA. Vitamin D elicits anti-inflammatory response, inhibits contractile-associated proteins, and modulates Toll-like receptors in human myometrial cells. Reprod Sci. 2013;20(4):463–475.
ChenYHYuZFuL. Vitamin D3 inhibits lipopolysaccharide-induced placental inflammation through reinforcing interaction between vitamin D receptor and nuclear factor kappa B p65 subunit. Sci Rep. 2015;5:10871.
54.
MalikMBrittenJLCoxJ. Cytokine regulation central to ulipristal mediated leiomyoma treatment. Fertil Steril. 2016;106(3):e280.
55.
IkhenaDELiuSKujawaSBulunSYinP. Silibinin inhibits progesterone induced RANKL expression in human uterine leiomyoma cells. Fertil Steril. 2016;106(3):e280.
56.
TalRSegarsJH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update. 2014;20(2):194–216.
57.
XuQOharaNChenW. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod. 2006;21(9):2408–2416.
58.
MantellDJOwensPEBundredNJMawerEBCanfieldAE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000;87(3):214–220.
59.
ChungIHanGSeshadriM. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009;69(3):967–975.
